Research directory

Clinical trials for IBD

Below are clinical trials currently recruiting participants in the United States.

125 studies

Ultrasound-Guided Surgical Margins for Terminal Ileal Crohn's Disease

This randomized study compares ultrasound-guided and standard surgical margin selection in adults having ileocolic resection for terminal ileal Crohn's disease.

Crohn's Disease (CD)

Phase: Na
Age range: 18 Years and older
Enrollment: 44 participants

1 recruiting site

Updated Jul 2, 2026

Recruiting

NCT07184931

Phase 3 duvakitug induction study for active Crohn’s disease

Phase 3 study of injected duvakitug versus placebo in people with moderately to severely active Crohn’s disease.

Crohn's Disease

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 980 participants

301 recruiting sites

Updated Jul 1, 2026

Recruiting

NCT07501078

Aquamin to Prevent Inflammation in Ulcerative Colitis J-Pouches

A placebo-controlled study of Aquamin for people with ulcerative colitis who recently received a J-pouch without an ileostomy.

Ileal Pouch · Ulcerative Colitis

Phase: Phase 2
Age range: 5 Years–80 Years
Enrollment: 52 participants

1 recruiting site

Updated Jun 29, 2026

Recruiting

NCT06548542

Targeted Therapies for Adults With Moderate to Severe Crohn’s Disease

A randomized phase 2 study of four targeted therapies in adults with moderate to severe Crohn’s disease.

Crohn's Disease

Phase: Phase 2
Age range: 18 Years–75 Years
Enrollment: 540 participants

233 recruiting sites

Updated Jun 26, 2026

Recruiting

NCT06332534

Phase 3 Upadacitinib Study for Children With Active Crohn’s Disease

A phase 3 study of oral upadacitinib in children ages 2–17 with moderately to severely active Crohn’s disease after prior treatment problems.

Crohn's Disease

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 110 participants

81 recruiting sites

Updated Jun 24, 2026

Recruiting

NCT06867094

Phase 2 Study of SAR441566 for Adults With Moderate-to-Severe Ulcerative Colitis

A Phase 2 study comparing three oral SAR441566 dose regimens with placebo in adults with moderate-to-severe ulcerative colitis.

Colitis Ulcerative

Phase: Phase 2
Age range: 18 Years–75 Years
Enrollment: 204 participants

113 recruiting sites

Updated Jun 23, 2026

Recruiting

NCT06405087

Long-Term Vedolizumab Study in Children With Ulcerative Colitis or Crohn’s Disease

Long-term vedolizumab injections and safety follow-up are studied in children and teenagers with ulcerative colitis or Crohn’s disease from a prior study.

Crohn's Disease · Ulcerative Colitis

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 70 participants

54 recruiting sites

Updated Jun 22, 2026

Recruiting

NCT06631586

Microbiota Transplant Capsules for Crohn’s Disease

A randomized study comparing two encapsulated donor-microbiota products in adults with active Crohn’s disease.

Crohn Disease

Phase: Phase 2
Age range: 18 Years–89 Years
Enrollment: 120 participants

2 recruiting sites

Updated Jun 22, 2026

Recruiting

NCT07184944

Phase 3 Maintenance Study of Duvakitug for Active Crohn's Disease

A Phase 3 study comparing duvakitug injections with placebo in people continuing from specified Crohn's disease studies.

Crohn's Disease

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 751 participants

35 recruiting sites

Updated Jun 22, 2026

Recruiting

NCT05666960

Phase 1 Study of R-3750 for Mild to Moderate Ulcerative Colitis

A Phase 1 study of the oral probiotic R-3750 in adults with mild to moderate ulcerative colitis.

Ulcerative Colitis · Ulcerative Colitis Chronic · Ulcerative Colitis Chronic Mild · Ulcerative Colitis Chronic Moderate

Phase: Phase 1
Age range: 18 Years–65 Years
Enrollment: 36 participants

5 recruiting sites

Updated Jun 12, 2026

Recruiting

NCT06637631

Phase 2 Study of SAR441566 for Adults With Moderate to Severe Crohn’s Disease

A phase 2 study comparing three doses of oral SAR441566 with placebo in adults with moderate to severe Crohn’s disease.

Crohn's Disease

Phase: Phase 2
Age range: 18 Years–75 Years
Enrollment: 260 participants

139 recruiting sites

Updated Jun 12, 2026

Recruiting

NCT05579392

Bright Light Therapy and Intestinal Barrier Health in Crohn’s Disease or Colitis

A crossover study of morning bright light therapy in adults with Crohn’s disease or ulcerative colitis and circadian misalignment.

Inflammatory Bowel Disease

Phase: Na
Age range: 18 Years and older
Enrollment: 30 participants

2 recruiting sites

Updated Jun 9, 2026

Recruiting

NCT06976853

Tirzepatide or Advanced Biologic Therapy for Difficult-to-Treat Crohn's Disease

A study comparing tirzepatide with a different advanced biologic in adults with difficult-to-treat Crohn's inflammation of the small bowel.

Crohn Disease (CD)

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 60 participants

3 recruiting sites

Updated Jun 5, 2026

Recruiting

NCT07556718

Amitriptyline for IBS-Like Symptoms in Crohn's Disease Remission

A placebo-controlled study of amitriptyline for adults with Crohn's disease in remission who continue to have IBS-like digestive symptoms.

Quiescent Crohn's Disease (CD)

Phase: Phase 2
Age range: 18 Years–65 Years
Enrollment: 100 participants

1 recruiting site

Updated Jun 5, 2026

Recruiting

NCT05218850

Butyrate Enemas for Children and Young Adults With Ulcerative Colitis

A single-group study of 12 weeks of daily butyrate enemas in young people with mild to moderate ulcerative colitis.

Ulcerative Colitis

Phase: Phase 2
Age range: 7 Years–21 Years
Enrollment: 10 participants

1 recruiting site

Updated Jun 4, 2026

Recruiting

NCT05995353

Risankizumab in Children With Moderately to Severely Active Crohn's Disease

A phase 3 study of intravenous and injected risankizumab in children ages 2–17 with moderately to severely active Crohn’s disease.

Crohn's Disease

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 110 participants

82 recruiting sites

Updated May 29, 2026

Recruiting

NCT05781152

Healing After Anti-TNF Therapy in Children Newly Diagnosed With Crohn’s Disease

This study examines healing after guided anti-TNF therapy in children ages 6–17 with newly diagnosed Crohn’s disease.

Crohn Disease

Phase: Phase 4
Age range: 6 Years–17 Years
Enrollment: 900 participants

25 recruiting sites

Updated May 27, 2026

Recruiting

NCT06227910

Vedolizumab With or Without Upadacitinib for Active Crohn’s Disease

This study compares vedolizumab plus upadacitinib with vedolizumab plus placebo in adults with moderately to severely active Crohn’s disease.

Crohn's Disease

Phase: Phase 3
Age range: 18 Years–65 Years
Enrollment: 396 participants

112 recruiting sites

Updated May 27, 2026

Recruiting

NCT06764615

Long-term oral zasocitinib study for adults with Crohn’s disease or ulcerative colitis

An extension study of oral zasocitinib in adults with Crohn’s disease or ulcerative colitis who responded in specified parent studies.

Crohn's Disease · Ulcerative Colitis

Phase: Phase 2
Age range: 18 Years–75 Years
Enrollment: 192 participants

16 recruiting sites

Updated May 22, 2026

Recruiting

NCT07427017

Selenium or Placebo With Advanced Therapy for Active Ulcerative Colitis

A randomized trial of selenium versus placebo for adults with moderate-to-severe ulcerative colitis starting or switching advanced therapy.

Ulcerative Colitis (UC)

Phase: Phase 2
Age range: 18 Years–85 Years
Enrollment: 180 participants

1 recruiting site

Updated May 22, 2026